Autism Treatment Evaluation Checklist

Rimland, Bernard; Edelson, Stephen M.

doi:10.1037/t03995-000

Cited by 140 publications

(133 citation statements)

References 89 publications

Supporting

Mentioning

131

Contrasting

Unclassified

Order By: Relevance

“…The primary efficacy measure was the ATEC. 20 Other efficacy measures included the parent version of Nisonger Child Behaviour Rating Form (CBRF) and the Behaviour Problems Inventory (BPI). 21,22 The ATEC has been specifically designed to evaluate the effectiveness of treatment for autistic individuals.…”

Section: Methodsmentioning

confidence: 99%

Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions

Almeida²,

et al. 2009

View full text Add to dashboard Cite

Little has been reported on the factors, genetic or other, that underlie the variability in individual response, particularly for autism. In this study we simultaneously explored the effects of multiple candidate genes on clinical improvement and occurrence of adverse drug reactions, in 45 autistic patients who received monotherapy with risperidone up to 1 year. Candidate genes involved in the pharmacokinetics (CYP2D6 and ABCB1) and pharmacodynamics (HTR2A, HTR2C, DRD2, DRD3, HTR6) of the drug, and the brain-derived neurotrophic factor (BDNF) gene, were analysed. Using the generalized estimating equation method these genes were tested for association with drug efficacy, assessed with the Autism Treatment Evaluation Checklist, and with safety and tolerability measures, such as prolactin levels, body mass index (BMI), waist circumference and neurological adverse effects, including extrapyramidal movements. Our results confirm that risperidone therapy was very effective in reducing some autism symptoms and caused few serious adverse effects. After adjusting for confounding factors, the HTR2A c.-1438G4A, DRD3 Ser9Gly, HTR2C c.995G4A and ABCB1 1236C4T polymorphisms were predictors for clinical improvement with risperidone therapy. The HTR2A c.-1438G4A, HTR2C c.68G4C (p.C33S), HTR6 c.7154-2542C4T and BDNF c.196G4A (p.V66M) polymorphisms influenced prolactin elevation. HTR2C c.68G4C and CYP2D6 polymorphisms were associated with risperidone-induced increase in BMI or waist circumference. We thus identified for the first time several genes implicated in risperidone efficacy and safety in autism patients. Although association results require replication, given the small sample size, the study makes a preliminary contribution to the personalized therapy of risperidone in autism.

show abstract

Section: Methodsmentioning

confidence: 99%

Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions

Almeida²,

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Only significant changes in relation to the baseline according to bootstrap .01 alpha level are shown in the EEG and EMG time frequency plots. e. Parental assessment One parent rated the child on (1) the Vineland Adaptive Behavior Scale (VABS) (Sparrow and Cicchetti 1985) which is a well-known, wellstandardized, interview that measures developmental and behavioral skills; (2) the Social Responsiveness Scale (SRS) (Constantino et al 2003) which provides a quantitative metric of the type and severity of impairments in social functioning that are characteristic of ASD children and (3) the Autism Treatment Evaluation Checklist (ATEC) (Magiati et al 2011;Rimland and Edelson 1999) which is used to measure changes in ASD symptomology in response to treatment.…”

Section: Pre-and Post-tests: Evaluation Of Training Successmentioning

confidence: 99%

“…The tests used (ATEC, SRS, and VABS) are standardized parental assessments that are appropriate for measuring all aspects of every-day behavior of children with ASD (Magiati et al 2011;Rimland and Edelson 1999;Constantino et al 2003;Sparrow and Cicchetti 1985). The advantage of using these comprehensive parental assessments is that behavioral changes in the real-world rather than in laboratory settings can be determined, whereas the disadvantage is that they could be biased by parental expectations.…”

Section: Changes In Behavior Assessed By the Parentsmentioning

confidence: 99%

An Effective Neurofeedback Intervention to Improve Social Interactions in Children with Autism Spectrum Disorder

Friedrich

Sivanathan

Lim

et al. 2015

J Autism Dev Disord

View full text Add to dashboard Cite

Neurofeedback training (NFT) approaches were investigated to improve behavior, cognition and emotion regulation in children with autism spectrum disorder (ASD). Thirteen children with ASD completed pre-/post-assessments and 16 NFT-sessions. The NFT was based on a game that encouraged social interactions and provided feedback based on imitation and emotional responsiveness. Bidirectional training of EEG mu suppression and enhancement (8-12 Hz over somatosensory cortex) was compared to the standard method of enhancing mu. Children learned to control mu rhythm with both methods and showed improvements in (1) electrophysiology: increased mu suppression, (2) emotional responsiveness: improved emotion recognition and spontaneous imitation, and (3) behavior: significantly better behavior in every-day life. Thus, these NFT paradigms improve aspects of behavior necessary for successful social interactions.

show abstract

“…Importantly, no subject in either group reported a worsening in autistic symptoms. Parental ratings on the Autism Treatment Evaluation Checklist (ATEC; Rimland & Edelson, 2000) showed a 40% decrease in core autistic symptoms as a result of this intervention in the experimental group. Decreases in autistic symptoms were also found on the Gilliam Asperger's Disorder Scale (GADS; Gilliam, 2001), Gilliam Autism Rating Scale (GARS; Gilliam, 1995), Personality Inventory for Children, Second Edition (PIC-2; Lachar, & Gruber, 2001), and Behavior Rating Inventory of Executive Function (BRIEF; Gioia, Isquith, Guy & Kenworthy, 2000).…”

Section: Introductionmentioning

confidence: 99%

Connectivity-Guided EEG Biofeedback for Autism Spectrum Disorder: Evidence of Neurophysiological Changes

Coben¹,

Sherlin²,

Hudspeth³

et al. 2014

View full text Add to dashboard Cite

Recent studies have linked neural coherence deficits with impairments associated with Autism Spectrum Disorders (ASD). The current study tested the hypothesis that lowering neural hyperconnectivity would lead to decreases in autistic symptoms. Subjects underwent connectivity-guided EEG biofeedback, which has been previously found to enhance neuropsychological functioning and to lessen autistic symptoms. Significant reductions in neural coherence across frontotemporal regions and source localized power changes were evident in frontal, temporal, and limbic regions following this treatment. Concurrently, there were significant improvements on objective neuropsychological tests and parents reported positive gains (decreases in symptoms) following the treatment. These findings further validate EEG biofeedback as a therapeutic modality for autistic children and suggest that changes in coherence anomalies may be related to the mechanism of action.

show abstract

Autism Treatment Evaluation Checklist

Cited by 140 publications

References 89 publications

Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions

Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions

An Effective Neurofeedback Intervention to Improve Social Interactions in Children with Autism Spectrum Disorder

Connectivity-Guided EEG Biofeedback for Autism Spectrum Disorder: Evidence of Neurophysiological Changes

Contact Info

Product

Resources

About